asia pacific immunochemistry equipment Market

The Asia-Pacific immunochemistry market is expected to reach US$ 795.05 Mn in 2027 from US$ 409.44 Mn in 2018. The market is anticipated to grow with a CAGR of 7.8 % from 2019-2027.

The growth of the immunochemistry market is primarily attributed to the rising incidences of chronic and infectious diseases and the increasing geriatric population. However, the limitations associated with immunohistochemistry is likely to have a negative impact on market growth. On the other hand, development opportunities in the region are likely to have a positive impact on the growth of the Asia-Pacific immunochemistry market in the coming years.

Immunohistochemistry (IHC) refers to an important application monoclonal and polyclonal antibody for tissue determination and distribution of antigens of particular disease. It is majorly used to detect several infectious disorders like dengue, hepatitis, human immunodeficiency virus (HIV). Chronic medical conditions such as obesity, cancer, diabetes, heart disease, and stroke, are also considered to be the primary major applications of immunohistochemistry that helps in the diagnosis of these diseases. In other words, rapid urbanization, diets with more meat and salt, less physical activity and increased air pollution make people sick, while improvement in health and medical care has lowered the death rates associated with pneumonia, measles, diarrhea and infant diseases. National diabetes rates increased by more than 50%, from 4,206 prevalent cases per 100,000 in 2000 to 6,336 prevalent cases in 2017. An estimated 6.3% of the population now have diabetes. This equates to about 90 million people. And, in Taiwan, more than one-in-ten people have diabetes. Surveillance and operational research on foodborne-diarrheal infections, healthcare-associated infections, respiratory diseases, and viral hepatitis have increased awareness about antibiotic resistant organisms, identified risk factors for disease transmission, and helped reduce under-reporting of infections. Supported the development of evidence that contributed to a major revision of China?s seasonal influenza vaccination policy in 2018.

According to the National Council on Aging, approximately 80% of adults suffer from at least one chronic disease, whereas 77% of aged people suffer from two. These chronic diseases majorly comprise cancer, heart disease, diabetes, and stroke. Immunohistochemistry techniques help in the quantification and diagnosis of these diseases accurately and reliably. The rising in R&D expenditure in Asia-pacific region is thus likely to grow the immunohistochemistry market in the forecast period.

In 2018, the diagnostics segment accounted for the largest market share in the Asia-Pacific immunohistochemistry market by the application. The growing benefits of immunohistochemistry have prolonged technology usage to diagnose several chronic diseases. The application of the molecular diagnostics has allowed to treat the patients as per their genetic make-up also diagnosis through immunohistochemistry that helps to increase the use in precision medicine. Even the cost-effective nature of the immunochemistry is driving significant growth across the region.

In 2018, the antibodies held the largest market share of the immunochemistry market by the product that also anticipated to dominate the market in 2027. Moreover, the reagent segment is anticipated to register the highest CAGR during the forecast period in the market, since they form an essential component of any reaction and can be chosen as per the result to be obtained.

In 2018, the hospital & diagnostic laboratories segment held the most significant market share of the immunochemistry market, by the end-user. This segment is also anticipated to dominate the market in 2027. Besides, the segment is also expected to grow at the fastest rate during the coming years due to the rise in the prevalence of infectious diseases, cancer, and autoimmune disorders.

Some of the major primary and secondary sources for immunochemistry included in the report are, Federation of AIDS Organizations (AFAO), American Heart Association (AHA), HIV and AIDS organization (AVERT), Centers for Disease Control and Prevention (CDC), Centers for Diabetes and Endocrinology (CDE), Food and Drug Administration (FDA) and others.